Sofinnova Investments’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-1,381,149
| Closed | -$437M | – | 91 |
|
|
2023
Q4 | $437M | Hold |
1,381,149
| – | – | 24.45% | 1 |
|
|
2023
Q3 | $234M | Hold |
1,381,149
| – | – | 14.73% | 1 |
|
|
2023
Q2 | $300M | Sell |
1,381,149
-391,975
| -22% | -$84M | 19.62% | 1 |
|
|
2023
Q1 | $322M | Sell |
1,773,124
-300,000
| -14% | -$57.4M | 20.6% | 1 |
|
|
2022
Q4 | $407M | Hold |
2,073,124
| – | – | 24.17% | 1 |
|
|
2022
Q3 | $466M | Hold |
2,073,124
| – | – | 27.13% | 1 |
|
|
2022
Q2 | $262M | Buy |
2,073,124
+120,047
| +6% | +$13.8M | 21.84% | 1 |
|
|
2022
Q1 | $248M | Hold |
1,953,077
| – | – | 18.79% | 1 |
|
|
2021
Q4 | $256M | Hold |
1,953,077
| – | – | 14.94% | 2 |
|
|
2021
Q3 | $239M | Buy |
1,953,077
+636
| +0% | +$73.4K | 14.15% | 2 |
|
|
2021
Q2 | $223M | Hold |
1,952,441
| – | – | 12.83% | 2 |
|
|
2021
Q1 | $235M | Hold |
1,952,441
| – | – | 14.11% | 2 |
|
|
2020
Q4 | $198M | Hold |
1,952,441
| – | – | 11.81% | 2 |
|
|
2020
Q3 | $151M | Buy |
1,952,441
+66,839
| +4% | +$5.7M | 11.19% | 3 |
|
|
2020
Q2 | $210M | Hold |
1,885,602
| – | – | 13.25% | 1 |
|
|
2020
Q1 | $136M | Hold |
1,885,602
| – | – | 12.56% | 1 |
|
|
2019
Q4 | $142M | Buy |
1,885,602
+156,250
| +9% | +$6.84M | 10.24% | 3 |
|
|
2019
Q3 | $28.2M | Hold |
1,729,352
| – | – | 2.55% | 11 |
|
|
2019
Q2 | $34.6M | Buy |
+1,729,352
| New | +$34.6M | 3.18% | 11 |
|
Other funds holding KRTX
Sofinnova Investments's KRTX Position: Q1 2024 in Review
Sofinnova Investments sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 1,381,149 shares — an estimated $437M sold.
Sofinnova Investments first reported a position in KRTX in Q2 2019 and held it in 19 quarters. The position peaked at $466M in Q3 2022. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.
- Sofinnova Investments reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Sofinnova Investments sold 1,381,149 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $437M.
- Sofinnova Investments first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2019 and held it in 19 quarters.
- Sofinnova Investments's Karuna Therapeutics, Inc. Common Stock position peaked at $466M in Q3 2022.
- 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Sofinnova Investments's 13F filing for Q1 2024, filed 15 May 2024.